Literature DB >> 17827938

Therapy of gastroesophageal reflux: evidence-based approach to antireflux surgery.

Lars Lundell1.   

Abstract

BACKGROUND: Due to the chronic, relapsing nature of gastroesophageal reflux disease, lifelong therapeutic options have to be considered and recommended in many patients. Accordingly, surgical repair has to be evaluated based on modern, evidence-based methodologies.
METHODS: A careful review has been carried out of the relevant surgical literature also including trials incorporating direct comparisons between medical and surgical therapies. The outcome of such a survey has been structured according to the grading of evidence from highest grade I to the lowest III.
RESULTS: Grade I evidence exists to show that antireflux surgery is more effective than proton pump inhibition in the control of reflux-related symptoms. Side effects are burdening surgical repair, many of which do not decrease over time. Data are not consistent to show any benefit of surgery whenever health economic outcomes are required. Minor differences are in favor of laparoscopic operations and it does matter who is doing the operation and how the repair is completed. Better data are requested to assess the true long-term efficacy (>10 years) of corresponding operations.
CONCLUSION: Antireflux surgery is an effective and durable therapeutic modality in the long-term management of gastroesophageal reflux disease. 2007 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17827938     DOI: 10.1159/000103883

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  9 in total

1.  Antireflux surgery: efficacy, side effects, and other issues.

Authors:  Lars Lundell
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-03

2.  Treatment of GORD: Three decades of progress and disappointments.

Authors:  Jean Paul Galmiche; Frank Zerbib; Stanislas Bruley des Varannes
Journal:  United European Gastroenterol J       Date:  2013-06       Impact factor: 4.623

3.  Evidence-based appraisal in laparoscopic Nissen and Toupet fundoplications for gastroesophageal reflux disease.

Authors:  Cheng-Xiang Shan; Wei Zhang; Xiang-Min Zheng; Dao-Zhen Jiang; Sheng Liu; Ming Qiu
Journal:  World J Gastroenterol       Date:  2010-06-28       Impact factor: 5.742

4.  Is there a role for anything other than a Nissen's operation?

Authors:  Martin Fein; Florian Seyfried
Journal:  J Gastrointest Surg       Date:  2009-12-10       Impact factor: 3.452

5.  The impact of radiotherapy and GERD on in situ lifetime of indwelling voice prostheses.

Authors:  Paolo Boscolo-Rizzo; Carlo Marchiori; Alessandro Gava; Maria Cristina Da Mosto
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-11-16       Impact factor: 2.503

6.  Measurement of gastric pH in ambulatory esophageal pH monitoring.

Authors:  Shahin Ayazi; Jessica M Leers; Arzu Oezcelik; Emmanuele Abate; Christian G Peyre; Jeffrey A Hagen; Steven R DeMeester; Farzaneh Banki; John C Lipham; Tom R DeMeester; Peter F Crookes
Journal:  Surg Endosc       Date:  2008-12-06       Impact factor: 4.584

7.  Quality of life following laparoscopic Nissen fundoplication: assessing short-term and long-term outcomes.

Authors:  Ilmo Kellokumpu; Markku Voutilainen; Caj Haglund; Martti Färkkilä; Peter J Roberts; Hannu Kautiainen
Journal:  World J Gastroenterol       Date:  2013-06-28       Impact factor: 5.742

8.  Antireflux transoral incisionless fundoplication using EsophyX: 12-month results of a prospective multicenter study.

Authors:  Guy-Bernard Cadière; Michel Buset; Vinciane Muls; Amin Rajan; Thomas Rösch; Alexander J Eckardt; Joseph Weerts; Boris Bastens; Guido Costamagna; Michele Marchese; Hubert Louis; Fazia Mana; Filip Sermon; Anna K Gawlicka; Michael A Daniel; Jacques Devière
Journal:  World J Surg       Date:  2008-08       Impact factor: 3.352

9.  Laparoscopic common bile duct exploration four-task training model: construct validity.

Authors:  Alexis Sánchez; Natalia Otaño; Omaira Rodríguez; Renata Sánchez; Gustavo Benítez; Michael Schweitzer
Journal:  JSLS       Date:  2012 Jan-Mar       Impact factor: 2.172

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.